RESEARCH-USE BIOSIMILAR ANTIBODY
Emibetuzumab
Monoclonal antibody · IgG4
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.
TARGETMET
YMonoclonal antibody
CATALOGSC-BS-594
CATALOG NUMBERSC-BS-594
MOLECULAR WEIGHTApprox. 144.56 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.
Emibetuzumab is a recombinant research-use antibody directed against MET.